Melatonin alleviates acute lung injury through inhibiting the NLRP3 inflammasome.
Level 5 - mechanism / opinion, no new human data
Animal study (preclinical mouse model)
PubMed 26888116 · doi:10.1111/jpi.12322
What was done
Researchers evaluated the therapeutic effects of intratracheal (i.t.) administration of melatonin in a lipopolysaccharide (LPS)-induced mouse model of acute lung injury (ALI). They assessed pulmonary tissue damage, neutrophil and macrophage infiltration, and markers of NLRP3 inflammasome activation, including caspase-1, IL-1β, and extracellular histones.
What was found
The abstract provides no numerical data, effect sizes, or confidence intervals. Qualitatively, intratracheal melatonin reduced pulmonary injury and decreased macrophage and neutrophil infiltration into the lungs. It also inhibited NLRP3 inflammasome activation by suppressing extracellular histone release and blocking histone-induced NLRP3 inflammasome activation, which reduced lung levels of active caspase-1 and IL-1β.
Why it matters
This paper identifies a specific mechanism (the extracellular histone-NLRP3 inflammasome axis) and proposes a direct pulmonary delivery route for melatonin in inflammatory lung injury. These findings offer a mechanistic rationale for further preclinical and translational study in acute lung injury.
Limits
This is purely an in vivo rodent model; findings cannot be assumed to translate directly to human acute lung injury or ARDS. The abstract omits sample sizes, melatonin dosages, quantitative metrics, and statistical significance values. Safety and pharmacokinetics of intratracheal melatonin were not evaluated in clinical settings.
Cited by
- supports Melatonin reduces macrophage and neutrophil infiltration into the lungs in animal models of acute lung injury via inhibition of the NLRP3 inflammasome.